Vimarsana
Biggest News Aggregation in the World

Clinical Data Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Data Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Data Program Today - Breaking & Trending Today

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD - Vimarsana News

4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD

Published: February 4, 2024

51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable...

Source: marketscreener.com
Related Topics:
United StatesArshadm KhananiDavid KirnRobert KimJulian PeiKatherine SmithCorporate CommunicationsProgram UpdatesExchange CommissionGlobenewswire IncClinical Data ProgramEuropean UnionClinic ResearchSierra Eye AssociatesD Molecular Therapeutics IncMolecular TherapeuticsChief Executive OfficerChief MedicalEye AssociatesTrial Dose Expansion Cohort BackgroundSummary BaselineDose ExpansionInterim ResultsTreatment Diabetic Retinopathy StudyTerm Follow Up Update
4DMT Presents Positive Interim Data from Randomized Phase 2 - Vimarsana News

4DMT Presents Positive Interim Data from Randomized Phase 2

Published: February 4, 2024

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden...

Source: globenewswire.com
Related Topics:
United StatesDavid KirnKatherine SmithRobert KimJulian PeiArshadm KhananiClinic Research At Sierra Eye AssociatesProgram UpdatesEuropean UnionCorporate CommunicationsClinical Data ProgramExchange CommissionMolecular TherapeuticsChief Executive OfficerChief MedicalClinic ResearchSierra Eye AssociatesTrial Dose Expansion Cohort BackgroundSummary BaselineDose ExpansionInterim ResultsTreatment Diabetic Retinopathy StudyTerm Follow Up UpdatePopulation ExtensionExpansion Phase
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden - Vimarsana News

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

Published: January 29, 2024

Initial interim landmark data analysis will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024...

Source: marketscreener.com
Related Topics:
United StatesKatherine SmithJulian PeiArshadm KhananiReno School Of MedicineClinical Associate Professor At University Of NevadaClinical Research At Sierra Eye AssociatesClinical Data ProgramCorporate CommunicationsPrincipal InvestigatorMolecular TherapeuticsWebcast DetailsTreatment BurdenInterim Clinical DataDegeneration Presentation DetailsInterim ResultsRandomized PhaseExpansion StageHigh Need PatientsEmerging TherapiesClinical ResearchSierra Eye AssociatesClinical Associate ProfessorReno SchoolScientific Presentations